On Tuesday, the Centers for Medicare & Medicaid Services (CMS) announced the next 15 drugs that will be subject to government price negotiations. Starting next year, the number of new drugs selected annually will increase to 20. The drugs selected this year are the top 15 from CMS’s list of 50 potential drugs for selection. (Of course, the actual drugs selected in 2027 may differ from this, and their sales next year may be higher or lower than last year.) Admittedly, a retrospective review of a drug’s past sales is an imperfect metric for estimating the potential prospective savings from the government’s price negotiations.